Clinical stage biotech firm Emyria Limited (ASX: EMD) has achieved positive progress with its preclinical MDMA-inspired drug discovery programme with partner, the University of Western Australia and led by medicinal chemistry expert, Dr Matt Piggott.
Emyria and UWA have been actively growing and screening a unique drug-discovery pipeline of novel MDMA analogues to identify new chemical entities and drug candidates with the potential to address major unmet needs in mental health and neurological disorders. Emyria previously secured exclusive rights to all MDMA-like compounds created under the partnership with Prof. Piggott and UWA.
Additional compound synthesis and screening is ongoing and a fourth batch of 14 unique compounds, inspired by previous screening results, was recently prepared and shipped for preliminary screening with Eurofins. This brings the total number of unique compounds in the library to over 140.
Five high priority compounds have been shipped to the USA for evaluation with specialist neuroscience CRO, PsychoGenics and additional metabolic studies have commenced with an Australian CRO to help determine the metabolic half-life of a priority set of compounds.
Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:
Emyria RWD can help support drug development and care model improvement.